Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. is a preclinical-stage cell therapy company developing synthetic allogeneic iMSC (induced pluripotent stem cell-derived mesenchymal stem cell) therapies. Its lead program, ERNA-101, is designed to deliver immune-stimulating cytokines into the tumor microenvironment, with an initial focus on platinum-resistant ovarian cancer and a broader pipeline in autoimmune disease.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaPreclinical cell therapy candidates designed to modulate immune responses in cancer and autoimmune disease.
Custom development of induced pluripotent stem cell lines for a customer under a contract arrangement.
Option, sublicense, and partnership structures intended to monetize platform technology and future assets.
Preclinical research, assay development, and partner-supported development activities.
Asiakkaat
Ernexa’s direct customers have been limited and contract-based, including a customer for exclusive option/licensing rights and cell line customization work. More broadly, its future customers are likely to be pharmaceutical partners, biotech collaborators, and clinical or commercial licensees rather than end patients, since the company is still preclinical and not yet selling approved therapies.
Potential licensees or co-development partners that would pay for access to the iMSC platform and pipeline assets.
A contract customer that paid for iPSC line customization and related option/licensing rights.
Institutions such as MD Anderson that support preclinical validation and translational work.
Public or private funding sources that support research activities and reduce dilution.
Strategia
The company’s near-term strategy is to advance ERNA-101 through IND-enabling work, submit an IND in 2026, and begin a Phase I investigator-sponsored trial in the second half of 2026. It is also seeking strategic partnerships, out-licensing opportunities, and research grants to fund development while preserving capital.
Clinical entry is the key value inflection point for a preclinical biotech and validates the platform beyond lab data.
The company has stated it lacks sufficient capital for the next 12 months and needs non-dilutive or dilutive funding to continue operations.
A second program such as ERNA-201 can broaden the platform beyond oncology and improve partnering appeal.
Maantiede
Ernexa is headquartered in the United States and appears to conduct most of its operations there, including research activity through its Texas subsidiary. The company is also building an international development path, highlighted by participation in a Japan External Trade Organization acceleration program to support future market entry and collaboration in Japan.
Riskit
Ernexa is a development-stage biotech with no commercial product revenue and a stated going-concern risk, so financing execution is central to survival. Its programs also face high clinical, regulatory, and competitive uncertainty, especially in ovarian cancer where larger companies and approved therapies already compete for physician and payer attention.
- Insufficient capital to fund operationsVaikutus: KriittinenTodennäköisyys: Korkea
Management disclosed it will not have sufficient capital for the next 12 months without additional financing.
Kohdistuu: Corporate survival and program continuity
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
ERNA-101 is preclinical and may fail in IND-enabling studies, human trials, or later efficacy testing.
Kohdistuu: Lead asset value and partnering prospects
- Competitive displacement in ovarian cancerVaikutus: Korkea
Approved and late-stage therapies may reach the market before Ernexa, limiting adoption and pricing power.
Kohdistuu: Platinum-resistant ovarian cancer indication
- Nasdaq continued listing complianceVaikutus: KeskitasoTodennäköisyys: Korkea
The company disclosed risk of delisting if it fails minimum bid price or equity requirements.
Kohdistuu: Public market access and liquidity
Kirjanpito
Harkinnanvaraiset erätRevenue was recognized ratably or accelerated based on contract terms and assignment, making timing highly dependent on legal structure.
Vaikutus: Affects reported revenue and cost of revenues
Preclinical and licensing costs are expensed as incurred, which suppresses current earnings while development is ongoing.
Vaikutus: Affects operating loss and comparability across periods
Management uses qualitative and quantitative assessments, and stock price declines can trigger impairment risk.
Vaikutus: Could create non-cash charges and reduce equity
The company reported changes in fair value for notes, warrants, and derivative liabilities in prior periods.
Vaikutus: Can materially affect net loss and volatility
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Estrella Immunopharma, Inc.
ESLAW · Biological Products, (No Diagnostic Substances)
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Erasca, Inc.
ERAS · Pharmaceutical Preparations
Theriva Biologics, Inc.
TOVX · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
TuHURA Biosciences, Inc.
HURA · Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV is a Nevada-based clinical-stage immuno-oncology company focused on developing therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
Päivitetty: 24.9.2026